Ovarian cancer and triple-negative breast cancer are among the most lethal diseases affecting women, with few targeted therapies and high rates of metastasis. Cancer cells are capable of evading clearance by macrophages through the overexpression of antiphagocytic surface proteins called 'don't eat me' signals-including CD47 1 , programmed cell death ligand 1 (PD-L1) 2 and the beta-2 microglobulin subunit of the major histocompatibility class I complex (B2M) 3 . Monoclonal antibodies that antagonize the interaction of 'don't eat me' signals with their macrophage-expressed receptors have demonstrated therapeutic potential in several cancers 4,5 . However, variability in the magnitude and durability of the response to these agents has suggested the presence of additional, as yet unknown 'don't eat me' signals. Here we show that CD24 can be the dominant innate immune checkpoint in ovarian cancer and breast cancer, and is a promising target for cancer immunotherapy. We demonstrate a role for tumour-expressed CD24 in promoting immune evasion through its interaction with the inhibitory receptor sialic-acid-binding Ig-like lectin 10 (Siglec-10), which is expressed by tumour-associated macrophages. We find that many tumours overexpress CD24 and that tumourassociated macrophages express high levels of Siglec-10. Genetic ablation of either CD24 or Siglec-10, as well as blockade of the CD24-Siglec-10 interaction using monoclonal antibodies, robustly augment the phagocytosis of all CD24-expressing human tumours that we tested. Genetic ablation and therapeutic blockade of CD24 resulted in a macrophage-dependent reduction of tumour growth in vivo and an increase in survival time. These data reveal CD24 as a highly expressed, anti-phagocytic signal in several cancers and demonstrate the therapeutic potential for CD24 blockade in cancer immunotherapy.
. The binding of CD24 to Siglec-10 elicits an inhibitory signalling cascade, which is mediated by Src homology region 2 domain-containing phosphatases, SHP-1 and/or SHP-2. These phosphatases are associated with the two immunoreceptor tyrosine-based inhibition motifs in the cytoplasmic tail of Siglec-10, thereby blocking Toll-likereceptor-mediated inflammation and the cytoskeletal rearrangement required for cellular engulfment by macrophages [12] [13] [14] . Studies have shown that CD24 is expressed by several solid tumours 15, 16 ; however, a role for CD24 in modulating tumour immune responses has not yet been shown. We therefore sought to investigate whether CD24-mediated inhibition of the innate immune system could be harnessed by cancer cells as a mechanism of avoiding clearance by macrophages that express Siglec-10.
To assess the role of CD24-Siglec-10 signalling in regulating the macrophage-mediated immune response to cancer, we examined the expression of CD24 and Siglec-10 in various tumours and associated immune cells. RNA-sequencing data from The Cancer Genome Atlas (TCGA) and the Therapeutically Applicable Research to Generate Effective Treatment Program (TARGET) revealed high expression of CD24 in nearly all tumours analysed (Extended Data Fig. 1a ), as well as broad upregulation of CD24 expression in several tumours as compared to known innate immune checkpoints (Fig. 1a) . The largest upregulation of CD24-a log 2 fold increase of more than nine-was observed in ovarian cancer; in addition, CD24 expression was significantly higher in triple-negative breast cancer (TNBC) than in healthy breast cells or in oestrogen-and progesterone-receptor-positive (ER + PR + ) breast cancers (Extended Data Fig. 1b, c) . Stratification of patients by CD24 expression revealed increased relapse-free survival for patients with ovarian cancer and an overall survival advantage for patients with breast cancer with lower CD24 expression (Fig. 1b, c) . We investigated CD24 and SIGLEC10 expression at a cellular level within the tumour by using single-cell RNA-sequencing data from six primary samples of TNBC 17 (NCBI Sequence Read Archive: PRJNA485423; Fig. 1d , Extended Data Fig. 1d , e). TNBC cells exhibited robust expression of CD24, whereas its expression was weak in all other cell clusters, thus illustrating the potential of CD24 as a tumour-specific marker (Fig. 1d) . A substantial fraction of tumour-associated macrophages (TAMs) were found to express SIGLEC10, indicating the possibility of CD24-Siglec-10 interactions in TNBC (Fig. 1d) . CD24 expression was substantially higher than PD-L1 (also known as CD274) expression in all patients analysed (Extended Data Fig. 1f ), whereas CD47 was highly expressed by all cell types (Fig. 1d) . Fluorescence-activated cell sorting (FACS) analyses of primary human tumours revealed robust expression of the CD24 protein in breast cancer cells and ovarian cancer cells, and TAMs from both tumour types were found to express Siglec-10 ( Fig. 1e , f, Extended Data Fig. 2a ). Human peritoneal macrophages obtained from patients without cancer expressed low levels of Siglec-10 (Extended Data Fig. 2b ). Analysis of subsets of peripheral blood mononuclear cells revealed low expression of Siglec-10 and CD24 in T cells, natural killer cells and monocytes, whereas B cells were found to express modest levels of Siglec-10 and high levels of CD24 (Extended Data Fig. 2c, d ).
To investigate a role for CD24-Siglec-10 signalling in regulating the macrophage-mediated anti-tumour immune response (Fig. 2a) , we engineered a polyclonal subline of the normally CD24-positive MCF-7 human breast cancer cell line that was deficient in CD24 (ΔCD24). Although unstimulated (M0) human donor-derived macrophages expressed low levels of Siglec-10 as measured by FACS, the addition of two inhibitory cytokines-TGFβ1 and IL-10-induced robust expression of Siglec-10, indicating that Siglec-10 expression may be regulated by TAM-specific gene-expression programs 18 (Extended Data Fig. 2e ). Macrophages stimulated by TGFβ1 and IL-10 (M2-like)
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were less phagocytic than unstimulated macrophages at baseline levels (Extended Data Fig. 2f ). We found that stimulation with the classic M2-polarizing cytokine IL-4 was also sufficient to induce Siglec-10 expression (Extended Data Fig. 2g ). Co-culture of either wild-type or ΔCD24 cells with M2-like macrophages expressing Siglec-10 revealed that CD24 genetic deletion alone was sufficient to potentiate phagocytosis (Fig. 2b) . ΔCD24 cells were also significantly more sensitive to CD47 blockade (using Clone 5F9-G4 19 ) than were wild-type cells, suggesting the cooperativity of combinatorial blockade of CD24 and CD47. To measure phagocytic clearance by automated live-cell microscopy, GFP + wild-type and ΔCD24 cells were labelled with the pH-sensitive dye pHrodo Red 20 and were co-cultured with macrophages. Over the course of 36 h, we found that ΔCD24 cells were more readily engulfed and degraded in the low-pH phagolysosome, as compared with wildtype cells (Fig. 2c) .
The blockade of Siglec-10 using monoclonal antibodies augmented the phagocytic ability of macrophages, thereby confirming a role for Siglec-10 in inhibiting phagocytosis (Fig. 2d) . To further investigate the effect of Siglec-10 expression on phagocytosis, we knocked out the SIGLEC10 gene in donor-derived macrophages. Three days after electroporation with a single-guide RNA targeting the SIGLEC10 locus, we observed a marked reduction in Siglec-10 expression relative to cells electroporated with Cas9 alone (Cas9 control) (Fig. 2e) . SIGLEC10 knockout macrophages demonstrated significantly greater phagocytic ability than Cas9 control macrophages (Fig. 2f) .
Siglec-10 has been reported to interact with the highly sialylated form of CD24 13, 14 . Accordingly, we observed that binding of Siglec-10-Fc (Fc, crystallizable fragment) to MCF-7 cells was considerably reduced upon surface desialylation (Fig. 2g, Extended Data Fig. 3b ). This suggests that Siglec-10 has the capacity to recognize both protein and sialic acid ligands, and therefore probably has varied ligands that extend beyond CD24. Indeed, we observed that CD24 deletion alone is insufficient to completely abrogate Siglec-10-Fc binding in the presence of surface sialylation (Extended Data Fig. 3a, b) . However, in the absence of surface sialylation, Siglec-10-Fc binding was nearly abolished by CD24 deletion, suggesting that CD24 is the primary protein ligand for Siglec-10 ( Fig. 2h, Extended Data Fig. 3b ). We found that desialylation did not reduce the enhancement of phagocytosis that was observed upon CD24 deletion, indicating that CD24 sialylation is not required to inhibit phagocytosis (Extended Data Fig. 3c ). Neither recombinant Siglec-5-Fc nor Siglec-9-Fc were found to bind CD24 + MCF-7 cells, although both were highly expressed by donor-derived macrophages (Extended Data Fig. 3d-g ).
To investigate the human therapeutic potential of these findings, we examined whether direct monoclonal antibody (mAb) blockade of CD24 could enhance the phagocytosis of CD24 + human cancers by disrupting CD24-Siglec-10 signalling (Extended Data Fig. 4a ). Automated live-cell microscopy revealed that MCF-7 pHRodo Red + cells treated with a CD24-blocking mAb (clone SN3) 21 were more readily engulfed into the low pH phagolysosome, as demonstrated by an enhanced red signal over time (Fig. 2i, Extended Data Fig. 4b ). Substantial wholecell phagocytosis was observed by confocal microscopy upon treatment with anti-CD24 mAb, and dual blockade of both CD24 and CD47 further augmented cellular engulfment (Extended Data Fig. 4c,  d) . Similarly, FACS-based measurements revealed a robust increase in phagocytosis upon the addition of anti-CD24 mAb as compared to the IgG control, which was greater than the effect observed with CD47 blockade (Fig. 3a ; the gating strategy for in vitro phagocytosis is shown in Extended Data Fig. 5a ). The response to anti-CD24 mAb was found to be dose-dependent and saturable (Extended Data Fig. 5b ). CD24 blockade augmented the phagocytosis of all CD24-expressing cancer cell lines tested-including breast cancer (MCF-7), pancreatic AML  CHOL  TGCT  LGG  BRCA  ALL  ACC  UCEC  LIHC  GBM  STAD  BLCA  LUSC  LUAD  PRAD  THCA  KIRP  CCSK  CESC  PAAD  ESCA  HNSC  COAD  KIRC  KICH  READ   CD24  CD47  PD-L1  B2M   DLBCL   log 2 (differentially expressed genes Letter reSeArCH adenocarcinoma (Panc1), pancreatic neuroendocrine tumour (APL1) and small-cell lung cancer (NCI-H82)-and no effect was observed with CD24
− cells (U-87 MG) (Fig. 3b, Extended Data Fig. 5c ). Upon dual treatment with CD24-and CD47-blocking antibodies, the induction of phagocytosis was increased to levels nearly 30 times that of the baseline in some cancers. Although genetic deletion of CD47 alone did not alter the phagocytic susceptibility of MCF-7 cells, upon treatment with anti-CD24 mAb, ∆CD47 cells were more readily engulfed than were wild-type cells (Extended Data Fig. 5d ). Dual treatment of pancreatic adenocarcinoma cells with anti-CD24 mAb and cetuximab enhanced phagocytosis relative to either treatment alone, demonstrating a potential synergy between anti-CD24 mAb and anti-solid-tumour mAbs (Extended Data Fig. 5e ). An isotype-matched antibody against epithelial cellular adhesion molecule (EpCAM)-a surface marker that is highly expressed by MCF-7 cells-led to a modest increase in phagocytosis as compared to treatment with anti-CD24 mAb, which indicates that the vast majority of the observed increase in phagocytosis upon the addition of anti-CD24 mAb is due to loss of CD24 signalling and not due to Fc-mediated opsonization (Extended Data Fig. 6a ). Both M2-like and M0 macrophages were found to respond equally to opsonization by anti-EpCAM antibodies (Extended Data Fig. 6b) . Disruption of the interaction between the Fc portion of the anti-CD24 mAb and the Fc receptors-CD16 and CD32-led to a modest reduction in anti-CD24 mAb-induced phagocytosis, confirming that the Fc-mediated pro-phagocytic effect of the anti-CD24 mAb is minor (Extended Data Fig. 6c ).
All Siglec-10-expressing macrophages responded to CD24 blockade (Extended Data Fig. 6d) , and the magnitude of this response trended towards a correlation with Siglec-10 expression (Extended Data  Fig. 6e ). Genetic deletion of SIGLEC10 led to a marked reduction in the response to CD24 blockade, which indicates that anti-CD24 mAb specifically disrupts CD24-Siglec-10 signalling (Fig. 3c) . Expression of CD24 correlated with response to CD24 blockade as well as with baseline phagoytosis levels, suggesting that tissue-specific expression of CD24 is a dominant 'don't eat me' signal and highlighting the potential value of CD24 expression as a predictor of the innate anti-tumour immune response (Fig. 3d, Extended Data Fig. 6f) .
Ovarian cancer cells were collected from patients with metastatic ovarian cancer and were treated with anti-CD24 mAb in order to measure phagocytosis of primary human tumours. (Fig. 3e) . In these cases, CD24 blockade yielded a significantly greater effect than CD47 blockade, and dual treatment with both CD24-and CD47-blocking antibodies augmented phagocytosis at least additively (Fig. 3f) . Furthermore, treatment of primary human TNBC cells with anti-CD24 mAb promoted phagocytic clearance by macrophages, whereas in these cases CD47 blockade had no effect on phagocytosis; this indicates that anti-CD24 mAb may be efficacious in cancers that show resistance to CD47 blockade (Extended Data Fig. 6g ). 
To investigate whether the protection against phagocytosis conferred by CD24 could be recapitulated in vivo, GFP-luciferase . Three weeks after engraftment, we found that CD24-deficient tumours exhibited augmented levels of in vivo phagocytosis by infiltrating TAMs as compared to wild-type tumours, and TAMs that infiltrated the CD24-deficient tumours were also of a more inflammatory phenotype (Extended Data Figs. 7, 8a, b). Over weeks, we observed a robust reduction in the growth of ΔCD24 tumours as compared to wild-type tumours (Fig. 4a, b) . Notably, the sublines assessed had no measurable cell-autonomous differences in proliferation in vitro (Extended Data Fig. 8c ). After 35 days of growth, the polyclonal ΔCD24 tumours had become largely CD24 + , which is consistent with the selection against CD24 -cells by TAMs and the 
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+ cells that did not have biallelic CD24 deletion (Extended Data Fig. 8d, e) . TAM depletion did not significantly alter the burden of wild-type tumours, whereas the loss of TAMs largely abrogated the reduction of tumour growth that was observed in ΔCD24 tumours, indicating that increased TAM-mediated clearance of ΔCD24 cells was responsible for the diminished tumour burden (Fig. 4b, Extended Data Fig. 8f ). This reduction in tumour growthattributed to enhanced phagocytic clearance-resulted in a significant survival advantage for mice engrafted with CD24-deficient tumours (Fig. 4c) .
To determine whether the mouse homologue of human CD24-gene name Cd24a-could similarly confer protection against phagocytic clearance of cancer cells, we generated a subline of the mouse epithelial ovarian cancer line ID8 that lacked CD24 (ID8ΔCd24a). Wild-type or ΔCd24a cells expressing GFP were injected intraperitoneally into NSG mice. After one week of growth, we observed that loss of Cd24a was sufficient to significantly promote in vivo phagocytosis by NSG macrophages (Extended Data Fig. 9a) . To assess the effect of mouse CD24 in a syngeneic, fully immunocompetent setting, ID8 wild-type or ID8ΔCd24a cells were engrafted intraperitoneally into C57Bl/6J mice. We observed that loss of CD24 was sufficient to substantially reduce tumour growth over several weeks (Extended Data Fig. 9b, c) .
To demonstrate that the enhancement of anti-tumour immunity could be modulated by therapeutic blockade of CD24, NSG mice with established MCF-7 wild-type tumours were treated with anti-CD24 monoclonal antibody for two weeks. Anti-CD24 therapy resulted in significant reduction of tumour growth compared to the IgG-treated control (Fig. 4d, e, Extended Data Fig. 9d ).
Potential off-target effects of anti-CD24 mAb treatment in humans include depletion of B cells, owing to high CD24 expression by B cells. Indeed, phagocytic clearance of healthy B cells was observed upon treatment with anti-CD24 mAb (Extended Data Fig. 10a ). However, we found that-unlike anti-CD47 mAbs 4 -the anti-CD24 mAb demonstrated no detectable binding to human red blood cells, even though mouse CD24a is expressed by mouse red blood cells (Extended Data  Fig. 10b ).
CD24 is a potent anti-phagocytic, 'don't eat me' signal that is capable of directly protecting cancer cells from attack by Siglec-10-expressing macrophages. Monoclonal antibody blockade of CD24-Siglec-10 signalling robustly enhances clearance of CD24 + tumours, which indicates promise for CD24 blockade in immunotherapy. Both ovarian 23 and breast cancer have demonstrated weaker responses to anti-PD-L1/PD-1 immunotherapies than have other cancers [24] [25] [26] , which suggests that an alternative strategy may be required to achieve responses across a wide range of cancers. It is notable that the 'don't eat me' signals CD47, PD-L1, B2M-and now CD24-each involve macrophage signalling based on immunoreceptor-tyrosine-based inhibition motifs. This may indicate a conserved mechanism that leads to immunoselection of the subset of macrophage-resistant cancer cells, resulting in tumours that-by nature-avoid macrophage surveillance and clearance. CD24 expression may provide immediate predictive value of the responsiveness of tumours to existing immunotherapies, in that high CD24 expression may inhibit response to therapies that are reliant on macrophage function. Expression of CD24 and CD47 was found to be inversely related among patients with diffuse large B cell lymphoma (Extended Data Fig. 10c) . The percentage of patients with CD24 overexpression compares well with the response rates observed with anti-CD47 + rituximab combination therapy in this disease 4 , opening up the possibility that particular tumours might respond differentially to treatment with anti-CD24 and/or anti-CD47 mAbs. Determining the collective expression of pro-and anti-phagocytic signals expressed by cancers and associated macrophages could enable better prediction of which patients may respond to treatment. This work defines CD24-Siglec-10 as an innate immune checkpoint that is essential for mediating anti-tumour immunity, and provides evidence for the therapeutic potential of CD24 blockade, with particular promise for the treatment of ovarian and breast cancers. Table 1 . Survival analysis was performed by stratifying patients into high or low CD24 expression using median expression values, and Kaplan-Meier plots were generated and analysed using Prism 8. Twodimensional contour plots were generated using Plotly (Plotly Technologies) Single-cell RNA-sequencing analysis. Raw files from previously sequenced TNBC (accession number PRJNA485423) were downloaded from the NCBI Sequence Read Archive (ref. 17) . The 1,539 single-cell RNA-sequencing data was aligned to the human genome (GRCh38) using STAR (version 2.5.3a) and gene counts (gene models from ENSEMBL release 82) were determined using htseq-count (intersection-nonempty mode, secondary and supplementary alignments ignored, no quality score requirement). The expression matrix was transformed to gene counts per million (c.p.m.) sequenced reads for each cell. High-quality cells were defined as those that had at least 200,000 c.p.m. and at least 500 genes expressed. This resulted in 1,001 cells.
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Marker genes used in ref. 17 were used to determine cell types. This was done using UMAP (nonlinear dimensionality reduction algorithm) on log-transformed c.p.m. values for the marker genes and labelling each of the five clusters identified on the basis of which cell markers were most expressed (see Extended Data Fig. 1d ). Scatter plots were constructed using this UMAP transformation with colouring as described in the figure legends. Cell culture. All cell lines were purchased from the American Type Culture Collection (ATCC) with the exception of the APL1 cells, which were a gift from G. Krampitz (MD Anderson), and the ID8 cells, which were obtained from the laboratory of O.D. The human NCI-H82 and APL1 cells were cultured in RPMI+GlutaMax (Life Technologies) + 10% fetal bovine serum (FBS) + 100 U ml −1 penicillin/streptomycin (Life Technologies). Cell lines were not independently authenticated beyond the identity provided from the ATCC. The human MCF-7, Panc1 and U-87 GM cell lines were cultured in DMEM+GlutaMax + 10% FBS + 100 U ml −1 penicillin/streptomycin. The murine ovarian carcinoma cell line, ID8, was cultured in DMEM + 4% FBS + 10% insulin/transferrin/selenium (Corning) + 100 U ml −1 penicillin/streptomycin. All cells were cultured in a humidified, 5% CO 2 incubator at 37 °C. All cell lines were tested for mycoplasma contamination. Generation of MCF-7 and ID8 sub-lines. Parental MCF-7 and ID8 were infected with GFP-luciferase lentivirus in order to generate MCF-7-GFP-luc + and ID8-GFP-luc + cell lines, respectively. After 48 h, cells were collected and sorted by FACS in order to generate pure populations of GFP + cells. The MCF-7ΔCD24-GFP-luc + and ID8ΔCd24a-GFP-luc + sub-lines were generated by electroporating cells with recombinant CRISPR-Cas9 ribonucleoprotein (RNP), as described previously 5 . In brief, CRISPR-Cas9 guide RNA molecules targeting human CD24 and mouse Cd24a, respectively, were purchased as modified, hybridized RNA molecules (Synthego) and assembled with Cas9-3NLS nuclease (IDT) via incubation at 37 °C for 45 min. Next, 2 × 10 6 MCF-7-GFP-luc + or ID8-GFP-luc + cells were collected, combined with corresponding complexed Cas9/RNP and electroporated using the Lonza Nucleofector IIb using Kit V (VCA-1003). After 48 h of culture, genetically modified cells were collected and purified through at least three successive rounds of FACS sorting in order to generate pure cell lines. Sequences for the single-guide RNA (sgRNA) molecules used are as follows: human CD24 sgRNA: CGGUGCGCGGCGCGUCUAGC; hCD47 sgRNA: AAUAGUAGCUGAGCUGAUCC; and mouse Cd24a sgRNA: AUAUUCUGGUUACCGGGAAA. In vitro cell proliferation assay. Proliferation of the MCF-7 wild-type and MCF-7ΔCD24 cell lines was measured with live-cell microscopy using an Incucyte (Sartorius). Cells were each plated at around 10% confluence. Percentage confluence after cell growth was measured as per the manufacturer's instructions every 8 h for 64 h. Neuraminidase treatment and recombinant Siglec-binding assay. MCF-7 cells were treated with either neuraminidase (from Vibrio cholerae, Roche) (1 × 10 6 cells per 100 U per ml or neuraminidase that was heat-inactivated for 15 min at 95 °C before incubation for 1 h at 37 °C in serum-free medium, after which reactions were quenched with serum before analysis. Recombinant Siglecs (10, 5 and 9) were purchased as human Fc-fusion proteins from R&D Systems. Binding of recombinant Siglecs versus human IgG1 control was assayed at a concentration of 1 × 10 5 cells per mg per ml at 37 °C for 1 h, in the absence of EDTA. Cells were stained with a fluorescently conjugated anti-human Fc antibody (BioLegend) to enable the measurement of recombinant Siglec binding by flow cytometry. Macrophage generation and stimulation. Primary human donor-derived macrophages were generated as described previously 28 . In brief, leukocyte reduction system chambers from anonymous donors were obtained from the Stanford Blood Center. Peripheral monocytes were purified through successive density gradients using Ficoll (Sigma-Aldrich) and Percoll (GE Healthcare). Monocytes were then differentiated into macrophages by 7-9 days of culture in IMDM + 10% AB human serum (Life Technologies). Unless otherwise stated, macrophages used for all in vitro phagocytosis assays were stimulated with 50 ng ml −1 human TGFβ1 (Roche) and 50 ng ml −1 human IL-10 (Roche) on days 3-4 of differentiation until use on days 7-9. IL-4 stimulation was added at a concentration of 20 ng ml −1 on days 3-4 of differentiation until use on days 7-9. Human macrophage knockouts. Genetic knockouts in primary human donor-derived macrophages were performed as described previously 5 . In brief, sgRNA molecules targeting the first exon of SIGLEC10 were purchased from Synthego as modified, hybridized RNA molecules. The SIGLEC10 sgRNA sequence used is: AGAAUCUCCCAUCCAUAGCC. Mature (day 7) donor-derived macrophages were electroporated with Cas9 ribonuclear proteins using the P3 Primary Cell Nucleofection Kit (Lonza V4XP-3024). Macrophages were collected for analysis and functional studies 72 h after electroporation. Indel frequencies were quantified using TIDE software as described previously with all ethical guidelines for human subjects research to obtain samples from patients with ovarian cancer and breast cancer, and received informed consent from all patients. Single-cell suspensions of solid tumour specimens were attained by mechanical dissociation using a straight razor, followed by an enzymatic dissociation in 10 ml of RPMI + 10 μg ml −1 DNaseI (Sigma-Aldrich) + 25 μg ml
Liberase (Roche) for 30-60 min at 37 °C with vigorous pipetting every 10 min to promote dissociation. After a maximum of 60 min, dissociation reactions were quenched with 4 °C RPMI + 10% FBS, filtered through a 100-μm filter and centrifuged at 400g for 10 min at 4 °C. Red blood cells in samples were then lysed by resuspending the tumour pellet in 5 ml ACK Lysing Buffer (Thermo Fisher Scientific) for 5 min at room temperature. Lysis reactions were quenched by the addition of 20 ml RPMI + 10% FBS, and samples were centrifuged at 400g for 10 min at 4 °C. Samples were either directly analysed, or resuspended in Bambanker (Wako Chemicals), aliquoted into cryovials and frozen before analysis. FACS of primary human tumour samples. Single-cell suspensions of primary human tumour samples were obtained (described above), and frozen samples were thawed for 3-5 min at 37 °C, washed with DMEM + 10% FBS, and centrifuged at 400g for 5 min at 4 °C. Samples were then resuspended in FACS buffer at a concentration of 1 million cells per ml and blocked with monoclonal antibody to CD16/32 (Trustain fcX, BioLegend) for 10-15 min on ice before staining with antibody panels. Antibody panels are listed, with clones, fluorophores, usage purpose, and concentrations used in Supplementary Table 2 . Samples were stained for 30 min on ice, and subsequently washed twice with FACS buffer and resuspended in buffer containing 1 μg ml −1 DAPI before analysis. Fluorescence compensations were performed using single-stained UltraComp eBeads (Affymetrix). Gating for immune markers and DAPI was performed using fluorescence minus one controls, while CD24
+ and Siglec-10 + gates were drawn on the basis of appropriate isotype controls (see Extended Data Fig. 2a for gating strategy) . Flow cytometry was performed either on a FACSAria II cell sorter (BD Biosciences) or on an LRSFortessa Analyzer (BD Biosciences) and all flow cytometry data reported in this work was analysed using FlowJo. Human tumour gating schemes were as follows: human TAMs: DAPI Flow-cytometry-based phagocytosis assay. All in vitro phagocytosis assays reported here were performed by co-culture target cells and donor-derived macrophages at a ratio of 100,000 target cells to 50:000 macrophages for 1-2 h in a humidified, 5% CO 2 incubator at 37 °C in ultra-low-attachment 96-well U-bottom plates (Corning) in serum-free IMDM (Life Technologies). Cells with endogenous fluorescence were collected from plates using TrypLE Express (Life Technologies) before co-culture. Cells from cell lines that lack endogenous fluorescence-NCI-H82 and Panc1-were collected using TrypLE Express and fluorescently labelled with Calcein AM (Invitrogen) by suspending cells in PBS + 1:30,000 Calcein AM as per the manufacturer's instructions for 15 min at 37 °C and washed twice with 40 ml PBS before co-culture. For TNBC primary-sample phagocytosis assays, tumours were acquired fresh on the day of resection and dissociated as Letter reSeArCH described above. EpCAM + tumour cells were purified on an autoMACS pro separator (Miltenyi) by first depleting samples of myeloid cells using anti-CD14 microbeads (Miltenyi, 1:50) followed by an enrichment with anti-EpCAM microbeads (Miltenyi, 1:50). For primary ovarian cancer ascites assays, ovarian ascites samples were frozen as described above, thawed and directly labelled with Calcein-AM (Invitrogen) at a concentration of 1:30,000. For primary B cell phagocytosis assays, B cells were enriched from pooled donor peripheral blood mononuclear cell (PBMC) fractions using an autoMACS pro separator (Miltenyi) using anti-CD19 microbeads (Miltenyi, 1:50). For Fc-receptor blockade phagocytosis assays, macrophages were pre-treated with 10 μg ml −1 human Fc-receptor blocking solution (BioLegend) for 45 min at 4 °C, and subsequent co-culture with mAb-treated target cells was conducted in the presence of 10 μg ml −1 human Fc-receptor blocking solution. For all assays, macrophages were collected from plates using TrypLE Express. For phagocytosis assays involving treatment with monoclonal antibodies including anti-CD24 (Clone SN3, Novus Biologics) and anti-CD47 (Clone 5F9-G4, acquired from Forty Seven), all antibodies or appropriate isotype controls were added at a concentration of 10 μg ml −1
. After co-culture, phagocytosis assays were stopped by placing plates on ice, centrifuged at 400g for 5 min at 4 °C and stained with A647-labelled anti-CD11b (Clone M1/70, BioLegend) to identify human macrophages. Assays were analysed by flow cytometry on an LRSFortessa Analyzer (BD Biosciences) or a CytoFLEX (Beckman), both using a high-throughput auto-sampler. Phagocytosis was measured as the number of CD11b + GFP + macrophages, quantified as a percentage of the total CD11b + macrophages. Each phagocytosis reaction (independent donor and experimental group) was performed in technical triplicate as a minimum, and outliers were removed using GraphPad Outlier Calculator (https://www.graphpad.com/quickcalcs/Grubbs1.cfm). To account for innate variability in raw phagocytosis levels among donor-derived macrophages, phagocytosis was normalized to the highest technical replicate per donor. All biological replicates indicate independent human macrophage donors. See Supplementary Table 2 for antibodies and isotype controls used in this study, and Extended Data Fig. 5a for example gating. Response to anti-CD24 mAb was computed by the fold change in phagocytosis between anti-CD24 mAb treatment and IgG control. Time-lapse live-cell-microscopy-based phagocytosis assay. Non-fluorescently labelled MCF-7 cells were collected using TrypLE express and labelled with pHrodo Red succinimidyl ester (Thermo Fisher Scientific) as per the manufacturer's instructions at a concentration of 1:30,000 in PBS for 1 h at 37 °C, followed by two washes with DMEM + 10% FBS + 100 U ml −1 penicillin/streptomycin. Donor-derived macrophages were collected using TrypLE express and 50,000 macrophages were added to clear, 96-well flat-bottom plates and allowed to adhere for 1 h at 37 °C. After macrophage adherence, 100,000 pHrodo-Red-labelled MCF-7 cells + 10 μg ml −1 anti-CD24 antibody (SN3) were added in serum-free IMDM. The plate was centrifuged gently at 50g for 2 min in order to promote the timely settlement of MCF-7 cells into the same plane as adherent macrophages. Phagocytosis assay plates were then placed in an incubator at 37 °C and imaged at 10-20-min intervals using an Incucyte (Essen). The first image time point (reported as t = 0) was generally acquired within 30 min of co-culture. Images were acquired using a 20× objective at 800-ms exposures per field. Phagocytosis events were calculated as the number of pHrodo-red + events per well and values were normalized to the maximum number of events measured across technical replicates per donor. Thresholds for calling pHrodo-red + events were set on the basis of intensity measurements of pHrodo-red-labelled cells that lacked macrophages. High-resolution phagocytosis microscopy. Fluorescently labelled MCF-7 cells (mCherry + ) and donor-derived macrophages were collected as described above. Suspensions consisting of 50,000 macrophages and 100,000 MCF-7 cells + 10 μg ml −1 antibody or isotype control in serum-free IMDM were placed into an untreated 24-well plate, in order to allow for adherence of donor-derived macrophages while preventing MCF-7 adherence. Reactions were incubated for 6 h in an incubator at 37 °C. After incubation, wells were washed vigorously five times with serum-free IMDM in order to wash away non-phagocytosed MCF-7 cells. Whole-cell phagocytosis was evaluated using a Leica DMI 6000B fluorescent microscope and an Olympus IX83. High-resolution z-stack images were taken on a Zeiss LSM800 confocal microscope. All images were processed in ImageJ and Adobe Illustrator. In compliance with Stanford APLAC protocol (26270), mice in long-term tumour studies were continually monitored to ensure adequate body condition scores and to ensure that tumours were less than 2.5 cm in diameter and that there was less than 50% ulceration. Female mice were used for all studies. Investigators were not blinded for animal studies.
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In vivo phagocytosis analysis.
For ID8 peritoneal phagocytosis analysis, 4 × 10 6 ,
ID8-WT-GFP-luc
+ cells or ID8-ΔCd24a-GFP-luc + cells were engrafted into 6-8-week-old female NSG mice via intraperitoneal injection of single-cell suspensions in PBS. After 7 days, cells were collected by peritoneal lavage. For MCF-7 xenograft phagocytosis analysis, female NSG mice, 6-10 weeks of age, were engrafted with 4 × 10 6 MCF-7-WT-GFP-luc + cells or MCF-7-MCF-7-ΔCD24-GFP-luc + cells by injection of a single-cell suspension in 25% Matrigel Basement Membrane Matrix (Corning) + 75% RPMI orthotopically into the mammary fat pad. Tumours were allowed to grow for 28 days, after which tumours were resected and dissociated mechanically and enzymatically as described above. Single-cell suspensions of tumours were blocked using anti-CD16/32 (mouse TruStain FcX, BioLegend) for 15 min on ice as described above, before staining. Phagocytosis was measured as the percentage of CD11b In vivo xenograft tumour-growth experiments. Female NSG mice, 6-10 weeks of age, were engrafted with 4 × 10 6 MCF-7-WT-GFP-luc + cells or MCF-7-ΔCD24-GFP-luc + cells as described above. Tumours were measured using bioluminescence imaging beginning 7 days post-engraftment and continuing every 7 days until day 28. Mice were injected intraperitoneally with firefly d-luciferin at 140 mg kg −1 in PBS and images were acquired 10 min after luciferin injection using an IVIS Spectrum (Perkin Elmer). Total flux was quantified using Living Image 4.0 software. For survival analyses, deaths were reported as the days on which the primary tumour burden reached 2.5 cm and/or the body condition scoring values fell below those allowed by our animal protocols. In vivo macrophage depletion treatment study. Female NSG mice, 6-10 weeks of age, were depleted of macrophages as described previously 4 by treatment with 400 μg CSF1R antibody per mouse or PBS (vehicle) (BioXCell, Clone AFS98) three times per week for 18 days before engraftment, and throughout the duration of the experiment. Successful tissue resident macrophage depletion was confirmed by flow cytometry before tumour engraftment by peritoneal lavage and flow cytometry analysis (Extended Data Fig. 8f ). Macrophage-depleted animals or vehicle treated animals were randomized before being engrafted with either MCF-7-WT-GFP-luc + or MCF-7-ΔCD24-GFP-luc + cells as described above. Immunocompromised tumour treatment studies. Female NSG mice (6-8 weeks old) were engrafted with 4 × 10 6 MCF-7-WT-GFP-luc + cells. On day 5 after engraftment, the total flux of all tumours was measured using bioluminescence imaging and engraftment outliers were removed using GraphPad Outlier Calculator. Mice were randomized into treatment groups, receiving either anti-CD24 monoclonal antibody (clone SN3, Creative Diagnostics) or mouse IgG1 isotype control (clone MOPC-21, BioXcell). On day 5 after engraftment, mice received an initial dose of 200 μg and were subsequently treated every other day at a dose of 400 μg for two weeks. Bioluminescence imaging was performed throughout the study and after treatment withdrawal in order to assess tumour growth. In vivo immunocompetent growth experiments. Female C57Bl/6 mice, 6-8 weeks of age were injected intraperitoneally with 1 × 10 6 ID8-WT-tdTomatoluc + or ID8-ΔCd24a-tdTomato-luc + cells in PBS. Tumour growth was measured by weekly bioluminescence imaging, beginning two weeks after engraftment. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
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Irving L. Weissman Jun 13, 2019 Flow cytometry data was collected using FACSDiva 8.0.1 (BD). Bioluminescence data was collected using Living Image 4.2.
Flow cytometry data was analyzed using FACSDiva 8.0.1 (BD) and FlowJo 10 (Tree Star). Bioluminescence data was analyzed using Living Image 4.2. All graphs were generated and analyzed using GraphPad Prism 8. Indel analysis for gene knockouts was performed using TIDE 2.0.1. Single-cell RNA sequencing analysis was performed with STAR 2.5.3a. Contour plots were generated using Plotly 2018.
All primary data for all figures and supplementary figures are available from the corresponding authors upon request.
As listed in the Methods, phagocytosis assays were performed in a minimum of technical triplicate for a minimum of 3 human donors per treatment group. In some cases, donors or specific technical replicates were excluded on the pre-established criterion that they were found to be a significant outlier by the GraphPad Outlier Calculator (https://www.graphpad.com/quickcalcs/Grubbs1.cfm). In some cases, additional replicates of specific phagocytosis assay conditions were repeated as part of pilot experiments, or as confirmatory replicates, but only a discrete set of data performed under identical conditions was specifically reported.
For in vivo experiments, individual mice were removed from the study either prior to treatment, if found to be an engraftment outlier by bioluminescence imaging, or from the final analysis if, at end point, the mouse was found to be a significant outlier with regards to tumor growth. These exclusion criteria were established prior to tumor engraftment. All outlier calculations for in vivo experiments were performed using the GraphPad Outlier Calculator (https://www.graphpad.com/quickcalcs/Grubbs1.cfm). In some cases across additional experiments, including pilot experiments, additional mice were engrafted subcutaneously with relevant cell lines and followed for non-standard periods of time, or assessed for tumor growth at non-standard intervals, but only a discrete set of mice assessed under identical conditions was reported.
In vitro phagocytosis assays were performed in technical triplicate for a minimum of 3 human donors per treatment group with similar results and responses observed across donors and replicates. In vitro phagocytosis assays were performed across multiple experimental replicates, when possible, with the exceptions of the phagocytosis assays shown in Figure 2d (4 biological replicates, one experimental replicate), Figure  2g Whenever practical for in vivo experiments, multiple cohorts across experimental replicates were performed. The number of cohorts performed is listed in the figure legends pertinent for each in vivo experiment. We observed similar results across cohorts and across individual mice within each cohort, as represented in the figures.
For macrophage depletion experiments, mice pre-treated with either vehicle or anti-CSF1R mAb were randomized amongst treatment cohorts prior to engraftment with WT or CD24 KO MCF-7 tumors. Similarly, mice engrafted with MCF-7 tumors were randomized prior to treatment with anti-human CD24 mAb.
All experiments, including in vivo experiments, were performed by unblinded investigators as all experiments in this work contained internal controls to allow for quantification and data analysis.
All antibodies used in this work, clone, application, and supplier are listed in Supplementary Table 1 .
The anti-human CD24 antibody (Clone SN3, Novus Bio (NB100-64861) and Creative Biolabs (CSC-S170)) used for staining and treatment studies in this work was validated by Novus Bio in human peripheral blood granulocytes. This antibody was also validated by staining unmodified MCF-7 cells versus CD24 knockout MCF-7 cells (dilution assessed in this work 1:50). The SN3
